ChartMill · Oct 24, 2026
Vericel (NASDAQ:VCEL): Strong Growth Backed by a Constructive Technical Setup
Vericel (VCEL) pairs strong growth and profitability with a consolidating stock chart, offering a technical setup to watch near resistance.
VC
NASDAQ · VCEL
Vericel Corporation
Healthcare · Biotechnology
$41.09
Up+$0.58 (+1.43%)
Updated Nov 4, 2026, 5:09 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.89B
- P/E ratio
- 144.38
- Dividend yield
- 0.00%
- 52-week range
- $28.95 – $49.32
- Volume
- 635.6K
- Avg. volume
- 728.95K
Price performance · VCEL
VCEL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
VCEL closed at $41.09 after 21 trading sessions, up 2.60% for the selected period.
- Last close
- $41.09
- Period change
- +2.60%
- Period low
- $40.05
- Period high
- $43.27
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $40.52 | $41.50 | $40.28 | $41.09 | 635.6K |
| Nov 2, 2026 | $40.29 | $40.88 | $39.44 | $40.51 | 684.37K |
| Oct 30, 2026 | $43.02 | $43.02 | $40.01 | $40.26 | 598.74K |
| Oct 29, 2026 | $41.99 | $43.05 | $41.48 | $42.91 | 544.83K |
| Oct 28, 2026 | $43.05 | $43.50 | $40.59 | $41.09 | 680.19K |
| Oct 27, 2026 | $43.04 | $43.74 | $42.65 | $43.27 | 558.37K |
| Oct 26, 2026 | $42.73 | $43.83 | $42.30 | $43.04 | 634.75K |
| Oct 23, 2026 | $42.99 | $43.00 | $41.75 | $42.53 | 494.73K |
| Oct 22, 2026 | $41.21 | $43.01 | $40.02 | $42.97 | 604.94K |
| Oct 21, 2026 | $40.00 | $41.04 | $40.00 | $40.94 | 432K |
| Oct 20, 2026 | $40.81 | $41.025 | $39.97 | $40.58 | 475.26K |
| Oct 19, 2026 | $40.36 | $40.945 | $40.04 | $40.37 | 334.25K |
| Oct 16, 2026 | $41.07 | $41.55 | $39.71 | $40.13 | 737.15K |
| Oct 15, 2026 | $40.77 | $41.60 | $40.26 | $41.02 | 601.21K |
| Oct 14, 2026 | $39.90 | $40.31 | $39.595 | $40.25 | 384.55K |
| Oct 13, 2026 | $40.62 | $40.77 | $39.99 | $40.30 | 511.74K |
| Oct 12, 2026 | $40.30 | $40.81 | $39.00 | $40.62 | 432.88K |
| Oct 9, 2026 | $39.83 | $41.13 | $39.78 | $40.10 | 506.89K |
| Oct 8, 2026 | $40.53 | $40.935 | $39.8125 | $40.05 | 749.14K |
| Oct 7, 2026 | $39.67 | $41.40 | $39.50 | $40.74 | 647K |
| Oct 6, 2026 | $41.38 | $41.45 | $39.65 | $40.05 | 669.04K |
Latest VCEL news
The latest Smart Investors Daily articles mentioning VCEL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VCEL research
Overview
Company profile and research snapshot.
Company profile
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | Truist Securities | Buy | — |
| Jul 31, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the V
Benzinga · Oct 14, 2026
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $52
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $58 to $52.
Yahoo · Sep 26, 2026
Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain
Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key issue for you is whether that market value can be reconciled with what its cash flows imply through a Discounted Cash Flow (DCF) lens. The 31.4% one year return has rewarded existing holders, so any fresh money coming in now needs a clear view on what the...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
